Harvard Bio Rejects $5 Per Share Buyout Offer from Investor | GenomeWeb
NEW YORK (GenomeWeb News) – Harvard Bioscience's board of directors on Friday unanimously rejected a buyout offer from Skystone Advisors for $5 a share. 
 
Skystone, a Cayman Islands-incorporated LLC with operations in Boston, has been investing in Harvard Bio since 2005 and currently owns around 15 percent of the company. Its offer represents a premium of around 11 percent over Harvard Bio’s trading price of $4.50 Friday afternoon, and values the firm at roughly $154 million based on 30.8 million shares outstanding.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic analysis of pollutant-tolerant fish, and more.

Researchers have found a rare carbapenem resistance gene on a US pig farm, NBC News reports.

New York officials are considering the use of a familial DNA search to get a lead on a suspect in the strangulation death of a runner.

NIH Director Francis Collins has selected a retired Army major general and cardiologist for the CEO spot at the agency's embattled Clinical Center.